Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
BERKELEY, Calif., Jan. 04, 2018 -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 11, 2018, at 9:00 am Pacific Time.
To access the live webcast and subsequent archived recording of this and other company presentations, please visit Aduro's website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's STING Pathway Activator platform is designed to activate the STING receptor in immune cells, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in both a Phase 1 monotherapy study as well as a Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor. Aduro’s B-select monoclonal antibody platform is comprised of a number of immune modulating assets in research and development, including BION-1301, an anti-APRIL antibody. Aduro's pLADD program is based on proprietary attenuated strains of Listeria that have been engineered to express tumor neoantigens that are specific to an individual patient’s tumor. Other Listeria strains for lung and prostate cancers are being advanced by a partner. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Contact:
Alexandra Santos
Corporate Affairs & Investor Relations
510 809 9231
Media Contact:
Aljanae Reynolds
510 809 2452
[email protected]
